22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

G1 Therapeutics Inc management update

G1 Therapeutics Inc ., Chapel Hill, N.C.   Business: Hematology   Hired: Raj Malik as CMO, formerly CMO of Agennix AG ; and Greg Mossinghoff as CBO  ...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Divergent appetites

BioCentury's 12th annual European Iceberg survey projects one of the lowest financing demand figures ever for public biotechs, thanks to the robust funding environment over the last two years. But while private companies actually raised...
07:00 , Jul 1, 2013 |  BioCentury  |  Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Evotec, Harvard deal

Evotec partnered with the university to discover and develop small molecule inhibitors of peptidoglycan biosynthesis. Harvard will contribute undisclosed research and IP relating on proprietary assays, small molecule hits and x-ray crystallographic tools, while Evotec...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Agennix cancer, dermatology news

At Sept. 30, 2012, Agennix had €5.8 ($7.4 million) in cash and a nine-month net cash burn of €33 million ($42.4 million). Last August, Agennix unveiled details of a restructuring, including headcount cuts of 37...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Talactoferrin: Phase III data

Data from 94 patients with NSCLC in the discontinued, double-blind, U.S. Phase III FORTIS-C trial showed that twice-daily 1.5 g oral talactoferrin in combination with carboplatin plus paclitaxel as first-line treatment led to an investigator-reported...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Talactoferrin: Final Phase I/II data

Final data from a double-blind, U.S. Phase I/II trial in 120 pre-term infants showed that twice-daily 150 mg/kg talactoferrin missed the primary endpoint of reducing the incidence of nosocomial infections vs. placebo (10% vs. 15%,...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Onconova Therapeutics management update

Onconova Therapeutics Inc. , Newton, Pa.   Business: Cancer   Hired: Thomas McKearn as president of R&D, formerly VP of strategic clinical affairs at the Agennix Inc. unit of Agennix AG  ...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...